10 results about "Apoptosis induction" patented technology

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

This invention relates to the field of biomedical technology, and more particularly to a method for preparing mesenchymal stem cell apoptotic vesicles. The method primarily employs serum-free culture medium for 3D microsphere culture of stem cells, followed by induction of apoptosis into apoptotic vesicles using an apoptosis induction system, resulting in highly efficient apoptotic vesicles. This method significantly enhances the bidirectional immunomodulatory effect of stem cell-derived apoptotic vesicles, greatly expanding the application range and therapeutic efficacy of these vesicles. The serum-free culture medium avoids the safety risks and batch-to-batch variations associated with traditional culture media, and significantly improves the proliferation capacity, passage stability, and immunomodulatory effect of stem cells, enabling stable and efficient acquisition of apoptotic vesicles.

The disclosure provides synthetic cytotoxic cells, comprising a hydrogel microsphere and a TNF-related apoptosis-inducing ligand (TRAIL), or active fragment thereof. In aspects, the TRAIL or active fragment thereof is attached to the surface of the hydrogel microsphere. The disclosure further provides methods of preparing the synthetic cytotoxic cells and methods of use thereof in the treatment of cancer.

The application discloses application of convallatoxin in preparation of a medicine for resisting prostate cancer and belongs to the technical field of biological medicines. The application finds that the convallatoxin has the efficacy of resisting prostate cancer, and the increase of UPP1 expression can enhance the inhibiting effect or the apoptosis induction effect of the convallatoxin on prostate cancer cells. Compared with the group of using the convallatoxin alone, after the 22Rv1 cells overexpressing UPP1 are treated by the convallatoxin, the apoptosis rate of the cells is increased by about 4 times, which indicates that the increase of UPP1 expression can enhance the effect of the convallatoxin on inducing the apoptosis of the prostate cancer cells.

The application discloses a preparation method of a bone formation inducing biological additive based on red blood cell-derived apoptotic vesicles and application thereof, and the preparation method comprises the following steps: a, red blood cell apoptosis induction treatment; b, collection and purification of red blood cell-derived apoptotic vesicles RBC-ApoEVs through series differential ultracentrifugation; c, characterization and quality control of the apoptotic vesicles; d, acquisition, culture and basic identification of SHED; and e, determination of 0.5 mu g / mL as the optimal bone formation inducing synergistic concentration of the red blood cell-derived apoptotic vesicles RBC-ApoEVs. The bone formation inducing biological additive prepared by the preparation method can be used as a safe and efficient bone formation inducing synergistic agent, and can solve the problem that "proliferation promotion" and "differentiation promotion" are difficult to be coordinated, and can also avoid the dependence on exogenous growth factors and related risks. The bone formation inducing biological additive can be applied to in-vitro induction of SHED bone differentiation, bone regeneration cell suspension and bone tissue engineering compound.

The purpose of the present invention is to provide a novel means that targets M1 microglia and is useful for the treatment of central nervous system diseases and the like. Provided is an M1 microglia-targeting fusion peptide in which an M1 microglia-targeting peptide and an apoptosis-inducing peptide are directly or indirectly linked to each other, wherein the M1 microglia-targeting peptide is a peptide mentioned in (1) or (2): (1) a peptide which has a structure such that at least one cysteine residue is directly linked to each of both ends of the amino acid sequence represented by HHSSSAR (SEQ ID NO: 1) or an amino acid sequence formed by linking a plurality of the sequences; and (2) a peptide which comprises an amino acid sequence having a structure such that one amino acid residue is or a plurality of amino acid residues are deleted, substituted or added in the amino acid sequence for the peptide (1) and which targets M1 microglia.

The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin 17 (CDH17). The application also provides conjugates comprising the multispecific antigen-binding proteins, polynucleotides and recombinant vectors encoding the multispecific antigen-binding proteins, as well as host cells and methods for preparing the multispecific antigen-binding proteins. The application further provides pharmaceutical compositions comprising the multispecific antigen-binding proteins andmethods for treating a disease or disorder using the multispecific antigen-binding proteins.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.

This invention discloses an acidic polysaccharide from Gynostemma pentaphyllum, AGPA12, its purification and extraction method, and its application in the preparation of anti-pancreatic cancer drugs. AGPA12 is mainly composed of mannose, glucuronic acid, rhamnose, glucose, galactose, and fucose, with a molar ratio of 1.05:1.74:6.29:1.40:69.48:19.03. The polysaccharide was extracted using an α-amylase-assisted water extraction and alcohol precipitation method, and purified by DEAE-Sepharose FF ion exchange chromatography and Sepharose CL6B gel chromatography. In vitro experiments showed that AGPA12 had significant inhibitory effects on the proliferation and migration of human pancreatic cancer AsPC1 cells, and its mechanism was related to the regulation of the MAPK signaling pathway and the expression of apoptosis-related proteins. This invention provides a new approach for the development of Gynostemma pentaphyllum polysaccharides and their application in anti-pancreatic cancer drugs.

The present application relates to a kind of engineered stem cell nanometer apoptotic bodies, its preparation method includes the following steps: by 3,3'-diindolylmethane directional induction obtains the engineered stem cell rich in repair and anti-inflammatory signal molecules, and then the engineered stem cell is induced to apoptosis, and the supernatant is separated and obtained by collection, then the programmed tandem extrusion process is handled to the engineered apoptotic body, and the particle size uniformity of the engineered nanometer apoptotic body is prepared.The engineered nanometer apoptotic body of the present application can effectively improve the microenvironment around hair follicle and regulate hair growth cycle, significantly improve the hair density and regeneration rate of androgenetic alopecia model mice, provide a new strategy of safe, convenient and efficient for clinical hair regeneration treatment.